DVAX

Dynavax Technologies Corporation (DVAX)

About Dynavax Technologies Corporation (DVAX)

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Details

Daily high
$10.44
Daily low
$10.16
Price at open
$10.28
52 Week High
$15.15
52 Week Low
$9.74
Market cap
1.4B
Dividend yield
0.00%
Volume
1.6M
Avg. volume
1.6M
P/E ratio
95.43

Dynavax Technologies Corporation News

Details

Daily high
$10.44
Daily low
$10.16
Price at open
$10.28
52 Week High
$15.15
52 Week Low
$9.74
Market cap
1.4B
Dividend yield
0.00%
Volume
1.6M
Avg. volume
1.6M
P/E ratio
95.43